FDA’s Benefit-Risk Framework is Good, but Needs Work, BIO Says

Drug Industry Daily
A A
The FDA could further improve the transparency of its benefit-risk assessments in drug regulatory decisions by disclosing more information in complete response letters, BIO suggested in written comments to the agency.

To View This Article:

Login

Subscribe To Drug Industry Daily